VivoSeq
Oncology

Hairy Cell Leukemia

30

Pipeline Programs↗

15

Active Trials↗

14

Companies Involved↗

Hairy Cell Leukemia is an emerging landscape with 30 programs across 14 companies. The most active players are Bayer, Parkedale, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

11/100

Mech. Concentration

11/100

Completion Rate

90/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1P

Parkedale

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1Roche logo

Roche

3 programs

Phase 2Day One Biopharmaceuticals logo

Day One Biopharmaceuticals

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

28 of 32 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody413%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed9 · 35%
Recruiting8 · 31%
Active, not recruiting6 · 23%
Terminated1 · 4%
Approved for marketing1 · 4%
Enrolling by invitation1 · 4%

Clinical Trials

Trial Activity

26 trials

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06311227·20 enrolled
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04322383·40 enrolled
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06561360·86 enrolled
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00412594·150 enrolled
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT06965114·84 enrolled
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Recruiting·UUniversity of Giessen·Phase 2/3·NCT02131753·210 enrolled
A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment
Recruiting·National Cancer Institute (NCI)·N/A·NCT01087333·1,263 enrolled
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT04815356·27 enrolled
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT01059786·69 enrolled
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT00923013·175 enrolled
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03410875·30 enrolled
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT01841723·44 enrolled
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Active, not recruiting·SScripps Health·Phase 2·NCT05388123·20 enrolled
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT03805932·18 enrolled
A Multicenter Phase 2 Study of Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant (RiZan Regimen)
Enrolling by invitation·BBnai Zion Medical Center·Phase 2·NCT07690761·12 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)